Production (Stage)
Silence Therapeutics plc
SLNCF
$1.59
$0.6263.92%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.97M | -46.76M | -74.57M | -49.86M | -43.25M |
| Total Depreciation and Amortization | 587.60K | 601.60K | 592.60K | 601.20K | 598.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.59M | 1.34M | 17.40M | 8.09M | 10.35M |
| Change in Net Operating Assets | -2.79M | -23.60M | 1.32M | 5.33M | -16.18M |
| Cash from Operations | -71.58M | -68.42M | -55.25M | -35.84M | -48.49M |
| Capital Expenditure | -218.10K | -214.10K | -148.30K | -109.80K | -21.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.68M | -24.21M | -87.75M | -24.14M | -30.81M |
| Cash from Investing | -18.90M | -24.43M | -87.90M | -24.25M | -30.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 36.80K | 36.80K | 20.90K | 20.90K | 83.90K |
| Issuance of Common Stock | 7.30M | 140.30M | 151.81M | 158.22M | 160.50M |
| Repurchase of Common Stock | -7.38M | -7.38M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 8.28M | 8.28M | 539.10K | 185.10K | 185.10K |
| Cash from Financing | 10.25M | 143.25M | 154.39M | 161.85M | 164.77M |
| Foreign Exchange rate Adjustments | 58.60K | -208.40K | -6.24M | 1.92M | 1.45M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.18M | 50.20M | 5.00M | 103.69M | 86.90M |